Tag Archives: Ed Arce

Durect (DRRX) Gets a Buy Rating from H.C. Wainwright

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Durect (DRRX – Research Report), with a price target of $5.50. The company’s shares closed last Tuesday at $2.55. According to TipRanks.com, Arce is a

H.C. Wainwright Maintains a Buy Rating on Dicerna Pharma (DRNA)

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Dicerna Pharma (DRNA – Research Report) today and set a price target of $32.00. The company’s shares closed last Thursday at $22.85. According to TipRanks.com, Arce is a 5-star analyst

H.C. Wainwright Believes Arcturus Therapeutics (NASDAQ: ARCT) Won’t Stop Here

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report) today and set a price target of $62.00. The company’s shares closed last Monday at $39.74, close to its 52-week high of $41.09. According

Summit Therapeutics (SMMT) Receives a Buy from H.C. Wainwright

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Summit Therapeutics (SMMT – Research Report) today and set a price target of $4.00. The company’s shares closed last Thursday at $3.75. According to TipRanks.com, Arce is a 5-star analyst

H.C. Wainwright Remains a Buy on Aurinia Pharmaceuticals (AUPH)

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Aurinia Pharmaceuticals (AUPH – Research Report) today and set a price target of $32.00. The company’s shares closed last Monday at $16.74. According to TipRanks.com, Arce is a 5-star analyst

H.C. Wainwright Sticks to Its Buy Rating for Genfit SA (GNFT)

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Genfit SA (GNFT – Research Report) today and set a price target of $46.00. The company’s shares closed last Thursday at $16.75. According to TipRanks.com, Arce is a 4-star analyst